The estimated Net Worth of Christopher D Alafi is at least $10.4 Milione dollars as of 27 May 2021. Christopher Alafi owns over 47,325 units of Intra-Cellular Therapies Inc stock worth over $7,098,400 and over the last 10 years he sold ITCI stock worth over $3,017,186. In addition, he makes $240,737 as Independent Director at Intra-Cellular Therapies Inc.
Sign up
Christopher Alafi ITCI stock SEC Form 4 insiders trading
Christopher has made over 21 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 47,325 units of ITCI stock worth $1,897,733 on 27 May 2021.
The largest trade he's ever made was buying 625,000 units of Intra-Cellular Therapies Inc stock on 11 March 2015 worth over $15,000,000. On average, Christopher trades about 39,170 units every 41 days since 2014. As of 27 May 2021 he still owns at least 95,000 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Christopher Alafi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Alafi biography
Dr. Christopher D. Alafi Ph.D. is an Independent Director of Intra-Cellular Therapies, Inc. Dr. Alafi became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since January 2013. Dr. Alafi has been a Managing Partner of Alafi Capital Company, LLC, a venture capital firm and a principal stockholder of the Company, since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Dr. Alafi previously served as a director of ISTO Technologies, Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc. Dr. Alafi received a B.A. in Biology from Pomona College and a D.Phil. in Biochemistry from the University of Oxford.
What is the salary of Christopher Alafi?
As the Independent Director of Intra-Cellular Therapies Inc, the total compensation of Christopher Alafi at Intra-Cellular Therapies Inc is $240,737. There are 13 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.
How old is Christopher Alafi?
Christopher Alafi is 56, he's been the Independent Director of Intra-Cellular Therapies Inc since 2014. There are 12 older and 4 younger executives at Intra-Cellular Therapies Inc. The oldest executive at Intra-Cellular Therapies Inc is Richard Lerner, 81, who is the Independent Director.
What's Christopher Alafi's mailing address?
Christopher's mailing address filed with the SEC is 8 Admiral Dr, Emeryville, CA 94608, USA.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus e Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Christopher Alafi stock trades at Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO